Exploring biomarkers in cancer patients through various sample collections
An Exploratory Biomarker Analysis in Blood, Urine, Stools, Hair Follicles and Saliva of Patients With Malignant Disease
This study is testing whether collecting different types of samples from cancer patients can help us understand how their tumors respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cancer Research UK, Glasgow Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Glasgow) |
| Trial ID | NCT05574738 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate biomarkers in patients with confirmed malignant solid tumors who are about to start anti-cancer therapy or are attending for clinical assessments. Participants will provide samples of blood, urine, stools, hair follicles, or saliva, depending on their cancer type, to analyze changes in biomarkers before and after treatment. The study seeks to determine the relationship between these biomarkers and tumor response to treatment, potentially identifying new diagnostic or predictive markers for cancer. Sample collection will coincide with routine hospital visits, ensuring no additional burden on participants.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed malignant solid tumors who are starting or undergoing anti-cancer therapy.
Not a fit: Patients with medical or psychiatric disorders that contraindicate sample collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and predictive tools for cancer treatment.
How similar studies have performed: Other studies exploring biomarkers in cancer have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed malignant disease (solid tumour) or a diagnosis of malignant disease made using recognised clinical criteria. 2. Patients who are attending for clinical assessments at presentation; during a routine hospital visit for anti-cancer therapy, radiotherapy, surgery, or for whom no immediate specific therapy is planned; or at a follow-up hospital visit. 3. Written informed consent. 4. Age ≥18 years. 5. Able to comply with study protocol. Exclusion Criteria: (1) Any evidence of any medical or psychiatric disorders that would, in the opinion of the investigator, be a contra indication to venesection, urine, stool or saliva collection.
Where this trial is running
Glasgow
- Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Jeff Evans, Prof — Cancer Research UK, Glasgow
- Study coordinator: Eileen Soulis
- Email: eileen.soulis@glasgow.ac.uk
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.